Literature DB >> 34114641

The pathologic diagnosis of mantle cell lymphoma.

Shaoying Li1, Jie Xu2, M James You2.   

Abstract

Mantle cell lymphoma (MCL) is a mature B-cell non-Hodgkin lymphoma usually characterized by t(11;14) (q13;q32), or CCND1 translocation and Cyclin D1 over expression. A very small subset of MCL may lack the t(11;14) (q13;q32) translocation and Cyclin D1 over expression, but show alternative translocations involving CCND2 and CCND3, and over expression of SOX11. In general, MCL has been considered a very aggressive and incurable lymphoma and patients with MCL usually have a poor prognosis. However, indolent variants, including in situ mantle cell neoplasm and the recently recognized leukemic non-nodal MCL do exist. In recent years, genome-wide molecular genetic studies have revealed a characteristic MCL genetic profile. This review will focus on the pathologic diagnosis of MCL using the traditional morphological and immunophenotypic strategies combined with cytogenetic characteristics and recently identified molecular profile. Morphological subtypes, immunophenotypic variants, recently recognized indolent variants, as well as MCL risk stratification will also be discussed.

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 34114641     DOI: 10.14670/HH-18-351

Source DB:  PubMed          Journal:  Histol Histopathol        ISSN: 0213-3911            Impact factor:   2.303


  99 in total

Review 1.  SOX11, a key oncogenic factor in mantle cell lymphoma.

Authors:  Renée Beekman; Virginia Amador; Elias Campo
Journal:  Curr Opin Hematol       Date:  2018-07       Impact factor: 3.284

2.  Cyclin D1 expression and novel mutational findings in Rosai-Dorfman disease.

Authors:  Ezra Baraban; Sam Sadigh; Jason Rosenbaum; John Van Arnam; Agata M Bogusz; Chelsea Mehr; Adam Bagg
Journal:  Br J Haematol       Date:  2019-06-06       Impact factor: 6.998

3.  SOX11 promotes tumor protective microenvironment interactions through CXCR4 and FAK regulation in mantle cell lymphoma.

Authors:  Patricia Balsas; Jara Palomero; Álvaro Eguileor; Marta Leonor Rodríguez; Maria Carmela Vegliante; Ester Planas-Rigol; Marta Sureda-Gómez; Maria C Cid; Elias Campo; Virginia Amador
Journal:  Blood       Date:  2017-05-22       Impact factor: 22.113

4.  Increased number of chromosomal imbalances and high-level DNA amplifications in mantle cell lymphoma are associated with blastoid variants.

Authors:  S Beà; M Ribas; J M Hernández; F Bosch; M Pinyol; L Hernández; J L García; T Flores; M González; A López-Guillermo; M A Piris; A Cardesa; E Montserrat; R Miró; E Campo
Journal:  Blood       Date:  1999-06-15       Impact factor: 22.113

5.  CD10-positive mantle cell lymphoma: biologically distinct entity or an aberrant immunophenotype? Insight, through gene expression profile in a unique case series.

Authors:  Ariz Akhter; Etienne Mahe; Lesley Street; Payam Pournazari; Marco Perizzolo; Meer-Taher Shabani-Rad; Douglas A Stewart; Adnan Mansoor
Journal:  J Clin Pathol       Date:  2015-06-29       Impact factor: 3.411

Review 6.  Role of SOX11 and Genetic Events Cooperating with Cyclin D1 in Mantle Cell Lymphoma.

Authors:  Sílvia Beà; Virginia Amador
Journal:  Curr Oncol Rep       Date:  2017-06       Impact factor: 5.075

7.  Aberrant Bcl6 protein expression in mantle cell lymphoma.

Authors:  Francisca I Camacho; Juan F García; Juan C Cigudosa; Manuela Mollejo; Patrocinio Algara; Elena Ruíz-Ballesteros; Pablo Gonzalvo; Paloma Martín; Carlos Pérez-Seoane; Joaquín Sánchez-García; Miguel A Piris
Journal:  Am J Surg Pathol       Date:  2004-08       Impact factor: 6.394

8.  Uniparental disomies, homozygous deletions, amplifications, and target genes in mantle cell lymphoma revealed by integrative high-resolution whole-genome profiling.

Authors:  Sílvia Beà; Itziar Salaverria; Lluís Armengol; Magda Pinyol; Verónica Fernández; Elena M Hartmann; Pedro Jares; Virginia Amador; Luís Hernández; Alba Navarro; German Ott; Andreas Rosenwald; Xavier Estivill; Elias Campo
Journal:  Blood       Date:  2008-11-04       Impact factor: 22.113

9.  Expression of TP53 is associated with the outcome of MCL independent of MIPI and Ki-67 in trials of the European MCL Network.

Authors:  Sietse M Aukema; Eva Hoster; Andreas Rosenwald; Danielle Canoni; Marie-Hélène Delfau-Larue; Grzegorz Rymkiewicz; Christoph Thorns; Sylvia Hartmann; Hanneke Kluin-Nelemans; Olivier Hermine; Martin Dreyling; Wolfram Klapper
Journal:  Blood       Date:  2017-12-01       Impact factor: 22.113

10.  Incidence of preclinical manifestations of mantle cell lymphoma and mantle cell lymphoma in situ in reactive lymphoid tissues.

Authors:  Patrick Adam; Ana-Iris Schiefer; Sophie Prill; Tobias Henopp; Leticia Quintanilla-Martínez; Hans-Christian Bösmüller; Andreas Chott; Falko Fend
Journal:  Mod Pathol       Date:  2012-07-13       Impact factor: 7.842

View more
  1 in total

1.  Mantle Cell Lymphoma With Non-traumatic Splenic Rupture Requiring Emergency Splenectomy.

Authors:  Patrick D Plummer; Benjamin Yglesias; Adam Swiger; Penelope Mashburn
Journal:  Cureus       Date:  2022-05-02
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.